The gastrointestinal pharmacology of cannabinoids.
The digestive tract contains endogenous cannabinoids (anandamide and 2-arachidonylglycerol) and cannabinoid CB1 receptors can be found on myenteric and submucosal nerves. Activation of CB1 receptors inhibits gastrointestinal motility, intestinal secretion and gastric acid secretion. The enteric location of CB1 receptors could provide new strategies for the management of gut disorders.
Izzo
A A
AA
Department of Experimental Pharmacology, University of Naples Federico II, Italy. aaizzo@unina.it
Mascolo
N
N
Capasso
F
F
D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism / Q000502:physiology; D002186:Cannabinoids / Q000378:metabolism* / Q000627:therapeutic use; D004064:Digestive System / Q000187:drug effects / Q000378:metabolism*; D063388:Endocannabinoids; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D005769:Gastrointestinal Motility; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy / Q000378:metabolism; D053284:Polyunsaturated Alkamides; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists / Q000378:metabolism*
D001095:Arachidonic Acids; D002186:Cannabinoids; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C078814:anandamide